Report
Jehanne Leroy
EUR 1000.00 Purchase single report

Mediclinic International - Proxy report 22/07/208

Leadership changes

Danie Meintjes was replaced by Carol Van Der Merwe as CEO in June 2018. Danie Meintjes was then an Executive Director from June 2018 until August 2018 when he was appointed as a Non-Executive Director.

Spire Takeover

Takeover talks with Spire ended in November after Spire rejected Meclinic's bid in October.

Controlling shareholder

Shareholder should note that, unlike most UK companies, Mediclinic has a controlling shareholder. Remgro Ltd. owns 44.56% of the share capital. There is a relationship agreement in place whereby Remgro Ltd is entitled, for every 10% of the issued share capital held, to appoint a director to Board, up to a maximum of three. The appointment of a third director is subject to the Board maintaining a majority of independent Non- Executive Directors.

Item 3: Approve the dividend

The proposed dividend is the same as that of the previous fiscal year. However, it is not covered by earnings in the current year in which net income was negative. The Group's dividend policy is to target a pay-out ratio of between 25% and 30% of adjusted earnings. The Board may revise the policy at its discretion.

Item 8: Re-elect the Chairman

The Chairman was not considered independent upon appointment as he formerly served as Executive Chairman and MD of Mediclinic International Ltd, which was combined with the Company (then known as Al Noor Hospitals Group plc) in February 2016. He is also the Deputy Chairman of Remgro Ltd, the Company's controlling shareholder. ECGS considers that a former CEO should only hold the role of Chairman as a temporary appointment following a suitable cooling-off period.

He is also the Chairman of the Nomination Committee. The level of gender diversity on the board does not meet ECGS guidelines.

Underlying
Mediclinic International

Provider
Proxinvest
Proxinvest

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Analysts
Jehanne Leroy

Other Reports on these Companies
Other Reports from Proxinvest
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch